FDA Panel Rejects Novartis AG Drug for Gout
A U.S. advisory panel on Tuesday rejected a Novartis AG drug for gout over concerns about side effects, a setback for the company's efforts to expand use of the medicine.
A committee of Food and Drug Administration advisers voted 11-1 against recommending approval of Ilaris for treating gout attacks. The panel also voted 12-0 against Ilaris for delaying and reducing the frequency of future attacks.
A committee of Food and Drug Administration advisers voted 11-1 against recommending approval of Ilaris for treating gout attacks. The panel also voted 12-0 against Ilaris for delaying and reducing the frequency of future attacks.